

OPEN ACCESS

EDITED BY Wen Ouyang, Central South University, China

REVIEWED BY Jerry Lorren Dominic, Jackson Memorial Hospital, United States Debas Yaregal Melesse, University of Gondar Comprehensive Specialized Hospital, Ethiopia

*CORRESPONDENCE Xiaomei Guo ⊠ gxm4725@163.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 16 July 2024 ACCEPTED 27 September 2024 PUBLISHED 10 October 2024

CITATION

Guo J, Guo X, Liu W, Zhou A, Han J, Yi R, Dong L and Zhou Y (2024) Post-operative delirium in different age groups and subtypes: a systematic review of case reports. *Front. Neurol.* 15:1465681. doi: 10.3389/fneur.2024.1465681

COPYRIGHT

© 2024 Guo, Guo, Liu, Zhou, Han, Yi, Dong and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Post-operative delirium in different age groups and subtypes: a systematic review of case reports

Jiaming Guo^{1,2†}, Xiaomei Guo^{1*†}, Wei Liu³, Aoran Zhou², Jiayi Han², Runxin Yi², Lijuan Dong¹ and Yinhao Zhou¹

¹Department of Nursing, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China, ²The First School of Clinical Medicine, Xinxiang Medical University, Xinxiang, China, ³Department of Clinical Pharmacy, Zhongshan City People's Hospital, Zhongshan, China

Aims: To explore the clinical presentations and outcomes among different ages and subtypes of post-operative delirium patients.

Design: Systematic review of Published Cases.

Methods and data sources: We comprehensively searched PubMed, EMBASE, and MEDLINE for published case reports of post-operative delirium up to April 2023. The systematic review has been registered with PROSPERO. Two researchers independently conducted unblinded reviews of the full-text articles.

Results: This study included 116 patients with post-operative delirium. Compared to post-operative delirium patients aged 65 and above, those between 18 and 65 years old have lower rates of a history of hypertension, cardiovascular disease and urinary system disorder comorbidities, as well as higher usage rates of fentanyl analogs and lorazepam. Additionally, these patients exhibit lower incidences of anemia and renal failure, along with a lower mortality rate. Compared to post-operative delirium patients aged 65 and above, those under 18 years old have a higher rate of fentanyl analog usage and a higher incidence of post-operative delirium following neurological surgeries. Among the hypoactive, hyperactive, and mixed subtypes, the reasons for surgery, such as cardiovascular diseases, reproductive system diseases, and neurological disorders, significantly varied among these three subtypes. Furthermore, substance abuse history and medication usage patterns also significantly varied among these three subtypes.

Conclusions: Our investigation has revealed noteworthy insights into postoperative delirium in different patient populations. Notably, age emerged as a pivotal factor. Compared to elderly patients (\geq 65 years), those aged 18 to 65 demonstrate better prognosis. Additionally, patients younger than 18 years with post-operative delirium have a higher incidence of delirium following neurosurgical procedures compared to those elderly patients. Additionally, a strong association was found between a history of substance abuse and hyperactive delirium. Variations in drug use patterns were observed across different subtypes. Importantly, post-operative delirium patients younger than 18 years, as well as those aged 18 to 65 with mixed-subtype delirium, exhibited similar high mortality rates as elderly patients. This underscores the need for increased attention to post-operative delirium patients under 65 and highlights the necessity of rapid identification and early intervention for these populations at risk of poor outcomes.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023473383, Identifier [Registration ID: CRD 42023473383].

KEYWORDS

acute confusion, post-operative delirium, age, subtype, systematic review

1 Introduction

Post-operative delirium (POD) is a prevalent transient cerebral dysfunction that frequently arises in a significant proportion of older adults (\geq 65 years) undergoing surgical procedures (1). It is characterized by acute onset and fluctuations in consciousness and cognition, leading to increased morbidity, length of hospital stays, healthcare expenditure, and mortality (2–5). Extensive research has been conducted on post-operative delirium in older populations, highlighting various risk factors, such as highrisk surgical procedures; pain; comorbidity burdens; histories of neurological, cardiac, respiratory, and metabolic diseases; metabolic derangement; and deficient functional baseline (3). Recent studies have found that certain biomarkers may also have predictive value for the occurrence of post-operative delirium, such as the C-reactive protein albumin ratio (6) and serum ferritin (7).

Research on post-operative delirium has focused primarily on adults or elderly patients aged 65 years and older (4, 8-10). Due to the lower incidence and mortality rates (11), studies on the characteristics and prognosis of post-operative delirium in patients aged younger than 65 years are limited. Previous studies have indicated that both children and non-elderly adult patients exhibit atypical symptoms, posing challenges for early diagnosis in these two populations (12). Furthermore, our study revealed that children and nonelderly adult patients often experience prolonged hospital stays (Table 1, Supplementary material 1), which typically translates into increased utilization of healthcare resources and additional medical costs (13, 14). Notably, post-operative delirium patients under the age of 18 often have underdeveloped brain regions related to "post-operative delirium," which may result in significant differences in their clinical presentation and prognosis compared to other patient groups (15, 16). Therefore, understanding the unique clinical features and potential risk factors for post-operative delirium in children and non-elderly adults is of paramount importance. It assists healthcare professionals in better identifying and managing patients, devising targeted intervention measures, improving patient outcomes, and reducing both hospitalization duration and medical expenses.

Delirium is currently defined by three subtypes, hyperactive, hypoactive and mixed, according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (17). In patients, hyperactive delirium is characterized by anxiety, agitation, disturbance, and excessive excitability. Hypoactive delirium, on the other hand, is typically characterized by apathy, severe difficulty concentrating, and reduced verbal communication. Mixed delirium refers to patients who may exhibit both hyperactive and hypoactive features at different times (18). A systematic review from 2018 revealed that the hypoactive subtype of delirium patients in the intensive care unit had the highest pooled incidence (11%) and prevalence (17%) and was the most common subtype (19). Furthermore, hypoactive and mixed subtypes of post-operative delirium often led to worse outcomes and consume more healthcare resources (20). Various pathophysiological mechanisms may account for the emergence of delirium, but the mechanisms of these different subtypes are still not fully understood. However, comprehensive systematic studies summarizing the clinical course of different subtypes of patients are lacking to aid in understanding their pathophysiological mechanisms and establishing targeted treatment management.

Therefore, this study will explore the differences in clinical presentations and outcomes among post-operative delirium patients across different age groups and delirium subtypes. We divided the patients into three age groups: POD-J (age < 18), POD-Y (age > 18 and < 65), and POD-E (age > 65). Further, we will compare the clinical characteristics and outcomes of post-operative delirium patients in the POD-J and POD-Y groups with the more common and relatively easily identifiable elderly post-operative delirium patient (POD-E group). This comparison will help clinicians better understand the differing clinical manifestations and prognosis between patients in the POD-J and POD-Y groups vs. those in the POD-E group (aged \geq 65). This knowledge will assist clinicians in more rapidly identifying these potentially dangerous but often insidious cases, allowing for the early implementation of appropriate interventions to improve the prognosis of post-operative delirium patients. In addition, we classified patients into three subtypes: hyperactive, hypoactive, and mixed subtypes. We will further compare the clinical manifestations and outcomes among these three subtypes of post-operative delirium patients, which will enhance our understanding of the different subtypes, including their triggers, pathogenesis, and pathophysiological mechanisms. This knowledge will also inform the development of effective prevention strategies and interventions.

2 Methods

2.1 Data sources and searches

We used the following keywords, post-operative delirium, post-operative cognitive dysfunction, POD, POCD, and case reports, to systematically search the PubMed, EMBASE, and MEDLINE databases from their inception until April 2023. We aimed to identify and analyze all relevant case reports documenting TABLE 1 Clinical characteristics and outcomes of adult patients with post-operative delirium.

Clinical characteristics	POD-ALL	POD-Y (18 ≤ y < 65)	POD-E (y ≥ 65)	p-value ^a	
Number of patients	116	63	45		
Age (all)	55.71 ± 22.43	45.81 ± 13.52	77.16 ± 7.62	<0.001	
Age (female)	55.78 ± 21.60	45.93 ± 12.61	76.71 ± 7.97	<0.001	
Age (male)	55.65 ± 23.14	45.70 ± 14.30	77.54 ± 7.27	<0.001	
Male	61/115 (53.04%)	33/63 (52.38%)	24/45 (53.33%)	0.922	
Reasons for surgery					
Skeletal disorders	24/116 (20.69%)	14/63 (22.22%)	9/45 (20.00%)	0.781	
Cardiovascular diseases	22/116 (18.97%)	11/63 (17.46%)	9/45 (20.00%)	0.738	
Gastrointestinal diseases	23/116 (18.93%)	9/63 (14.29%)	13/45 (28.89%)	0.063	
Malignant neoplasm	12/116 (10.34%)	6/63 (9.52%)	6/45 (13.33%)	0.535	
Respiratory diseases	7/116 (6.03%)	3/63 (4.76%)	4/45 (8.89%)	0.644	
Reproductive system diseases	6/116 (5.17%)	6/63 (9.52%)	0/45 (0.00%)	0.088	
Neurological disorders	5/116 (4.31%)	3/63 (4.76%)	0/45 (0.00%)	0.373	
Urological disorders	4/116 (3.45%)	1/63 (1.59%)	3/45 (6.67%)	0.389	
Others	13/116 (11.21%)	10/63 (15.87%)	1/45 (2.22%)	0.047	
Anesthesia					
Regional	8/94 (8.51%)	4/54 (7.41%)	4/32 (12.50%)	0.688	
General	86/94 (91.49%)	49/54 (90.74%)	28/32 (87.50%)	0.912	
Preexisting cognitive dysfunction	16/109 (14.68%)	9/58 (15.52%)	7/43 (16.28%)	0.917	
Delirium history	2/108 (1.85%)	2/58 (3.45%)	0/42 (0.00%)	0.334	
Disease history					
Smoke	9/105 (8.57%)	7/56 (12.50%)	2/41 (4.88%)	0.356	
Alcohol	9/105 (8.57%)	8/56 (14.29%)	1/41 (2.44%)	0.103	
Drugs (cocaine etc.)	7/105 (6.67%)	7/56 (12.50%)	0/41 (0.00%)	0.051	
Common chronic disease	41/105 (39.05%)	14/56 (25.00%)	25/41 (60.98%)	<0.001	
Dyslipidemia	8/105 (7.62%)	3/56 (5.36%)	5/41 (12.20%)	0.403	
Diabetes	14/105 (13.33%)	5/56 (8.93%)	8/41 (19.51%)	0.118	
Hypertension	24/105 (22.86%)	6/56 (10.71%)	17/41 (41.46%)	<0.001	
Coronary heart disease	8/105 (7.62%)	2/56 (3.57%)	6/41 (14.63%)	0.113	
Asthma	5/105 (4.76%)	2/56 (3.57%)	3/41 (7.32%)	0.719	
COPD	5/105 (4.76%)	1/56 (1.79%)	3/41 (7.32%)	0.403	
Intraoperative complications					
Hypotension	2/59 (3.39%)	1/33 (3.03%)	1/20 (5.00%)	0.617	
Hypertension	1/59 (1.69%)	1/33 (3.03%)	0/20 (0.00%)	0.623	
Desaturation	0/59 (0.00%)	0/33 (0.00%)	0/20 (0.00%)	-	
Blood transfusion	2/59 (3.39%)	0/33 (0.00%)	2/20 (10.00%)	0.138	
Subtypes					
Hypoactive	38/89 (42.70%)	7/57 (12.28%)	4/31 (12.90%)	1	
Hyperactive	63/89 (70.79%)	34/57 (59.65%)	21/31 (67.74%)	0.454	
Mixed	15/89 (16.85%)	3/57 (5.26%)	6/31 (19.35%)	0.086	

TABLE 1 (Continued)

Clinical characteristics	POD-ALL	POD-Y (18 ≤ y < 65)	POD-E (y ≥ 65)	<i>p</i> -value ^a		
Time of surgery						
Mean \pm SD min	214.93 ± 125.77	286.10 ± 158.16	192.3 ± 103.76	0.091		
Comorbidities						
Cardiovascular	39/106 (36.79%)	11/56 (19.64%)	27/43 (62.79%)	<0.001		
Gastrointestinal	18/106 (16.98%)	11/56 (19.64%)	7/43 (16.28%)	0.667		
Central nervous system	18/106 (16.98%)	9/56 (16.07%)	8/43 (18.60%)	0.740		
Respiratory	15/106 (14.15%)	7/56 (12.50%)	7/43 (16.28%)	0.593		
Hematological	5/106 (4.72%)	2/56 (3.57%)	3/43 (6.98%)	0.761		
Urinary	13/106 (12.26%)	3/56 (5.36%)	10/43 (23.26%)	0.009		
Mental disorders	22/106 (20.75%)	15/56 (26.79%)	8/43 (18.60%)	0.339		
Anxiety	6/106 (5.66%)	5/56 (8.93%)	1/43 (2.33%)	0.347		
Depression	7/106 (6.60%)	5/56 (8.93%)	2/43 (4.65%)	0.669		
Cancer	16/106 (15.09%)	6/56 (10.71%)	10/43 (23.26%)	0.093		
Else	27/106 (25.47%)	16/56 (28.57%)	32/43 (74.42%)	<0.001		
Anesthetic drugs						
Sevoflurane	18/50 (36.00%)	11/43 (25.58%)	2/12 (16.67%)	0.796		
Isoflurane	7/50 (14.00%)	6/43 (13.95%)	1/12 (8.33%)	0.979		
Nitrous oxide	8/50 (16.00%)	5/43 (11.63%)	0/12 (0.00%)	0.502		
Propofol	29/50 (58.00%)	21/43 (48.84%)	6/12 (50.00%)	0.943		
Ketamine	5/50 (10.00%)	4/43 (9.30%)	1/12 (8.33%)	1		
Thiopental sodium	3/50 (6.00%)	3/43 (6.98%)	0/12 (0.00%)	0.470		
Lidocaine	16/50 (32.00%)	8/43 (18.60%)	5/12 (41.67%)	0.201		
Bupivacaine	3/50 (6.00%)	1/43 (2.33%)	1/12 (8.33%)	0.392		
Medicine						
Fentanyl analogs	40/102 (39.22%)	27/62 (43.55%)	8/36 (22.22%)	0.034		
Fentanyl	18/102 (17.65%)	9/62 (14.52%)	6/36 (16.67%)	0.776		
Sufentanil	5/102 (4.90%)	4/62 (6.45%)	1/36 (2.78%)	0.748		
Remifentanil	5/102 (4.90%)	5/62 (8.06%)	0/36 (0.00%)	0.148		
Morphine	7/102 (6.86%)	8/62 (12.90%)	10/36 (27.78%)	0.067		
Hydrocodone	8/102 (7.84%)	5/62 (8.06%)	3/36 (8.33%)	1		
Succinylcholine	7/102 (6.86%)	7/62 (11.29%)	0/36 (0.00%)	0.092		
Vecuronium	5/102 (4.90%)	5/62 (8.06%)	0/36 (0.00%)	0.080		
Rocuronium	9/102 (8.82%)	8/62 (12.90%)	1/36 (2.78%)	0.190		
Benzodiazepines	49/102 (48.04%)	33/62 (53.23%)	11/36 (30.56%)	0.569		
Lorazepam	16/102 (15.69%)	13/62 (20.97%)	2/36 (5.56%)	0.041		
Midazolam	30/102 (29.41%)	20/62 (32.26%)	6/36(16.67%)	0.092		
Dexmedetomidine	10/102 (9.80%)	8/62 (12.90%)	2/36 (5.56%)	0.417		
Diphenhydramine	6/102 (5.88%)	4/62 (6.45%)	2/36 (5.56%)	1		
Chlorpromazine	5/102 (4.90%)	4/62 (6.45%)	1/36 (2.78%)	0.748		
Flupentixol	31/102 (30.39%)	19/62 (30.65%)	12/36 (33.33%)	0.783		
Quetiapine	10/102 (9.80%)	6/62 (9.68%)	4/36 (11.11%)	1		

TABLE 1 (Continued)

Clinical characteristics	POD-ALL	POD-Y (18 ≤ y < 65)	POD-E (y ≥ 65)	<i>p</i> -value ^a	
Olanzapine	7/102 (6.86%)	4/62 (6.45%)	2/36 (5.56%)	1	
NSAIDs	20/102 (19.61%)	10/62 (16.13%)	9/36 (25.00%)	0.284	
Aspirin	7/102 (6.86%)	2/62 (3.23%)	5/36 (13.89%)	0.117	
Atropine	10/102 (9.80%)	9/62 (14.52%)	1/36 (2.78%)	0.132	
Neostigmine	9/102 (8.82%)	7/62 (11.29%)	2/36 (5.56%)	0.559	
Glucocorticoids	15/102 (14.71%)	11/62 (17.74%)	4/36 (11.11%)	0.379	
Furosemide	7/102 (6.86%)	4/62 (6.45%)	3/36 (8.33%)	1	
Catecholamines	16/102 (15.69%)	4/62 (6.45%)	6/36 (16.67%)	0.206	
Epinephrine	7/102 (6.86%)	4/62 (6.45%)	2/36 (5.56%)	1	
Norepinephrine	5/102 (4.90%)	0/62 (0.00%)	5/36 (13.89%)	0.011	
Dopamine	4/102 (3.92%)	3/62 (4.84%)	1/36 (2.78%)	1	
Statins	5/102 (4.90%)	2/62 (3.23%)	3/36 (8.33%)	0.528	
Ondansetron	9/102 (8.82%)	5/62 (8.06%)	2/36 (5.56%)	0.954	
Antibiotics	23/102 (22.55%)	12/62 (19.35%)	11/36 (30.56%)	0.207	
Adverse events					
Post-operative hypotension	6/104 (5.77%)	3/55 (5.45%)	3/41 (7.32%)	1	
Post-operative hypertension	6/104 (5.77%)	3/55 (5.45%)	3/41 (7.32%)	1	
Arrhythmia	18/104 (17.31%)	9/55 (16.36%)	9/41 (21.95%)	0.488	
Anemia	6/104 (5.77%)	0/55(0.00%)	6/41 (14.63%)	0.012	
Kidney failure	5/104 (4.81%)	0/55 (0.00%)	5/41 (12.20%)	0.028	
Else	50/104 (48.08%)	23/55 (41.82%)	26/41 (63.41%)	0.036	
ICU	32/98 (32.65%)	17/49 (34.69%)	14/41 (34.15%)	0.957	
Mechanical ventilation	33/98 (33.67%)	14/49 (28.57%)	16/41 (39.02%)	0.295	
Days of hospitalization					
Mean \pm SD day	29.80 ± 43.96	37.00 ± 55.44	20.08 ± 18.97	0.888	
Recurrence	17/116 (14.66%)	6/63 (9.52%)	10/45 (22.22%)	0.067	
Follow-up	28/116 (24.14%)	19/63 (30.16%)	8/45 (17.78%)	0.143	
Outcome					
Death (all)	11/113 (9.73%)	1/61(1.64%)	9/44 (20.45%)	0.004	
Death (female)	4/52 (7.69%)	1/61 (1.64%)	3/20 (15.00%)	0.045	
Death (male)	7/61 (11.48%)	0/61 (0.00%)	6/24 (25.00%)	<0.001	

POD, post-operative delirium; y, year; COPD, chronic obstructive pulmonary disease; SD, Standard Deviation; min, minutes; NSAIDs, non-steroidal anti-inflammatory drugs; ICU, intensive care unit. ^a Means comparison between POD-Y group and POD-E group using Chi-Squared test. The bold values refer to statistical significance (P < 0.05).

the occurrence of post-operative delirium. The search terms used for PubMed and MEDLINE were as follows: "[emergence delirium"[MeSH Terms] OR "emergence"[All Fields] AND "delirium"[All Fields]) OR "emergence delirium"[All Fields] OR "post-operative"[All Fields] AND "delirium"[All Fields]) OR "post-operative delirium"[All Fields] OR "POD"[All Fields] OR ("post-operative cognitive complications"[MeSH Terms] OR ("post-operative"[All Fields] AND "cognitive"[All Fields] AND "complications"[All Fields]) OR "post-operative cognitive complications"[All Fields]] OR "post-operative cognitive complications"[All Fields]] OR ("post-operative"[All Fields]] AND "cognitive"[All Fields]] OR ("post-operative"[All Fields]] OR "post-operative cognitive dysfunction"[All Fields]) OR "POCD"[All Fields]) AND "case reports"[Publication Type] OR "case report"[All Fields]). The search details of the EMBASE query were as follows: "post-operative delirium or POD or post-operative cognitive dysfunction or POCD" and "case report."

2.2 Inclusion and exclusion criteria

The inclusion criteria were as follows: (I) the type of article was a case report or case series; (II) the study was conducted within an

inpatient hospital setting, and patients had to be diagnosed with post-operative delirium; (III) the case details needed to encompass one or more of the following elements: age, sex, subtypes, reasons for surgery, disease history, comorbidities, medicine, outcome, etc.; and (IV) the full text of the articles was accessible. In alignment with the exclusion criteria, conference abstracts, non-English and Chinese literature, meta-analyses and systematic reviews, reviews, comments, and unrelated studies were excluded.

2.3 Data selection and extraction

Two researchers independently conducted unblinded reviews of the full-text articles and abstracts. A total of 6,354 articles were identified through keyword searches of the databases. After a manual screening process, 6,254 articles were excluded based on the selection criteria. The details of the selection process are presented in Figure 1. From the remaining 100 articles (including 116 patients), various details were extracted, including the publication year, patient demographics (sex, age, etc.), reasons for surgery, anesthesia method, medical history, intraoperative complications, subtypes of post-operative delirium, comorbidities, anesthetic drugs, medication, adverse events, followup, and clinical outcomes. The articles describing cases of post-operative delirium resulting from different causes and the details of the clinical characteristics and outcomes of these patients were systematically extracted and documented in the Supplementary material 1.

2.4 Quality assessment

Two independent reviewers evaluated the quality of the studies by utilizing the Joanna Briggs Institute (JBI) Critical Appraisal tools for Case Reports (21). The JBI tool assessed the quality of case reports across eight criteria, such as clear identification of the patient's condition, detailed information on treatment interventions, and appropriate follow-up. Each criterion is rated as "Yes" or "No." The more "Yes" responses, the higher the methodological quality of the case report and the more reliable the evidence provided. Each of the eight criteria in the JBI assessment tool is scored 1 point, with a total score of eight points. The results of the quality assessment are detailed in the Supplementary material 3.

2.5 Statistical analysis

We conducted a statistical analysis of the case-derived data. Continuous variables are presented as the mean and standard deviation. For comparing continuous variables, a two-tailed unpaired t test was used. Comparisons of the data between different cohorts were conducted using Pearson's chi-square test or Fisher's exact test. A two-sided p value < 0.05 indicated statistical significance. IBM SPSS Statistics 27.0.1 was used for all the statistical analyses. Furthermore, GraphPad Prism 8.0.1 was

used to construct a heatmap and volcano plot, enhancing the visual representation of the data.

2.6 Guidelines statement

The work has been reported in line with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (22).

3 Results

3.1 Quality assessment of case reports

One hundred case reports were included in review and the quality assessment, conducted using the Joanna Briggs Institute Critical Appraisal tools for Case Reports, demonstrated that 86 studies scored more than 7, 7 studies scored 6, 4 studies scored 5, 2 studies scored 4, and only one study scored 3. The average JBI score for all included studies was 7.34 (see Supplementary material 3).

3.2 Overview of all patients

A total of 116 patients with post-operative delirium (POD-ALL) were described in the 100 studies, and their clinical characteristics and outcomes are detailed in Table 1. Of these patients, 61 (53.04%) were male, with an average age of 55.71 \pm 22.43 years. The most common reason for surgery was skeletal disorders (20.69%), followed by cardiovascular diseases (18.97%) and gastrointestinal diseases (18.93%). Eighty-six patients (91.49%) received general anesthesia, and 8 patients (8.51%) received regional anesthesia. Sixteen of the patients (14.68%) had preexisting cognitive dysfunction, and 2 patients (1.85%) had a history of delirium. The majority of these patients had a history of common chronic diseases (39.05%), including hypertension (22.86%), diabetes (13.33%), dyslipidemia (7.62%), and coronary heart disease (7.62%); asthma (4.76%); chronic obstructive pulmonary disease (4.76%); smoking (8.57%); alcohol consumption (8.57%); and drugs (6.67%). The most frequent comorbidities were cardiovascular diseases (36.79%), followed by mental disorders (20.75%), including anxiety (5.66%), and depression (6.60%). The rates of intraoperative complications, including hypotension (3.39%), hypertension (1.69%), and blood transfusion (3.39%), were low, and the average duration of surgery was 214.93 min, with a standard deviation of 125.77 min. Additionally, 38 patients (42.70%) presented as hypoactive, 63 (70.79%) as hyperactive and 15 (16.85%) as mixed. Commonly used anesthetics included propofol (58.00%), sevoflurane (36.00%), and lidocaine (32.00%). The medicines that patients took most often were benzodiazepines (48.04%), including lorazepam (15.69%) and midazolam (29.41%); fentanyl analogs (39.22%), including fentanyl (17.65%), sufentanil (4.90%), and remifentanil (4.90%); flupentixol (30.39%); antibiotics (22.55%); and nonsteroidal antiinflammatory drugs (19.61%). Remarkably, there was a high incidence of mechanical ventilation (33.67%) and admission to the intensive care unit (32.65%). The average length of hospitalization was 29.80 days, with a standard deviation of 43.96 days. A portion



of the patients experienced recurrence (14.66%), and 11 patients (9.73%) died-4 females (7.69%), and 7 males (11.48%).

3.3 Clinical features and prognosis of patients with post-operative delirium across different age groups

Among patients aged 65 and older, there is a high incidence of post-operative delirium and poor prognosis, which urgently deserve our attention. However, we always overlook the identification of clinical characteristics and investigations of related prognoses in patients younger than 65 years (the POD-J and POD-Y groups). Tables 1, 2 display the clinical characteristics and outcomes of post-operative delirium patients in the POD-J, POD-Y, and POD-E cohorts.

Sixty-three patients were included in the POD-Y group; the average age was 45.81 ± 13.52 years, and 33 patients (52.38%) were men. For the POD-Y group, the most prevalent reason for surgery was skeletal disorders (22.22%), followed by cardiovascular diseases (17.46%) and gastrointestinal diseases (14.29%). Fortynine patients (90.74%) in the POD-Y group received general

anesthesia, and 4 patients (7.41%) received regional anesthesia. Of all patients in the POD-Y cohort, 9 patients (15.52%) had preexisting cognitive dysfunction, and 2 patients (3.45%) had a history of delirium. Common chronic diseases (25.00%) constituted a majority of the disease history in the POD-Y group and included hypertension (10.71%), diabetes (8.93%), dyslipidemia (5.36%), coronary heart disease (3.57%), asthma (3.57%), chronic obstructive pulmonary disease (1.79%), alcohol (14.29%), smoking (12.50%), and drugs (12.50%). In the POD-Y group, the most common comorbidities were mental disorders (26.79%), including anxiety (8.93%) and depression (8.93%), followed by cardiovascular diseases (19.64%), gastrointestinal diseases (19.64%), central nervous system diseases (16.07%), and respiratory diseases (12.50%). The rate of intraoperative complications, including hypotension (3.03%) and hypertension (3.03%), in the POD-Y group was low, and the average duration of surgery was 286.10 min, with a standard deviation of 158.16 min. Additionally, 7 patients (12.28%) in the POD-Y group presented with hypoactivity, 34 (59.65%) with hyperactivity and 3 (5.26%) with mixed symptoms. Propofol (48.84%), sevoflurane (25.58%), and lidocaine (18.60%) were frequently used for anesthesia in the POD-Y group. The medicines that the POD-Y group took most commonly were benzodiazepines (53.23%), which included

TABLE 2 Clinical characteristics and outcomes of post-operative delirium patients under 18.

Clinical characteristics	POD-J (y < 18)	POD-E (y ≥ 65)	<i>p</i> -value ^a		
Number of patients	7	45			
Age (all)	6.94 ± 5.36	77.16 ± 7.62	<0.001		
Age (female)	7.67 ± 3.68	76.71 ± 7.97	<0.001		
Age (male)	6.40 ± 6.28	77.54 ± 7.27	<0.001		
Male	4/7 (57.15%)	24/45 (53.33%)	1		
Reasons for surgery					
Neurological disorders	2/7 (28.57%)	0/45 (0.00%)	0.016		
Others	5/7 (71.43%)	1/45 (2.22%)	<0.001		
Anesthesia					
General	7/7 (100.00%)	28/32 (87.50%)	0.437		
Subtypes					
Hyperactive	5/7 (71.43%)	21/31 (67.74%)	1		
Mixed	2/7 (28.57%)	6/31 (19.35%)	0.978		
Anesthetic drugs					
Sevoflurane	5/6 (83.33%)	2/12 (16.67%)	0.026		
Isoflurane	1/6 (16.67%)	1/12 (8.33%)	0.569		
Nitrous oxide	3/6 (50.00%)	0/12 (0.00%)	0.044		
Propofol	2/6 (33.33%)	6/12 (50.00%)	0.867		
Lidocaine	3/6 (50.00%)	5/12 (41.67%)	1		
Bupivacaine	1/6 (16.67%)	1/12 (8.33%)	0.569		
Medicine					
Fentanyl analogs	5/7 (71.43%)	8/36 (22.22%)	0.032		
Fentanyl	3/7 (42.86%)	6/36 (16.67%)	0.293		
Morphine	3/7 (42.86%)	10/36 (27.78%)	0.730		
Benzodiazepines	5/7 (71.43%)	11/36 (30.56%)	0.105		
Lorazepam	1/7 (14.29%)	2/36 (5.56%)	0.421		
Midazolam	4/7 (57.14%)	6/36 (16.67%)	0.067		
Olanzapine	1/7 (14.29%)	2/36 (5.56%)	0.421		
NSAIDs	1/7 (14.29%)	9/36 (25.00%)	0.900		
Epinephrine	1/7 (14.29%)	2/36 (5.56%)	0.421		
Ondansetron	2/7 (28.57%)	2/36 (5.56%)	0.118		
Adverse Events					
Abdominal pain	1/7 (14.29%)	1/41 (2.44%)	0.273		
Heart failure	1/7 (14.29%)	3/41 (7.32%)	0.480		
ICU	1/7 (14.29%)	14/41 (34.15%)	0.544		
Mechanical ventilation	1/7 (14.29%)	16/41 (39.02%)	0.402		
Recurrence	1/7 (14.29%)	10/45 (22.22%)	1		
Outcome					
Death (all)	1/7 (14.29%)	9/44 (20.45%)	1		
Death (female)	0/3 (0.00%)	3/20 (15.00%)	0.644		
Death (male)	1/4 (25.00%)	6/24 (25.00%)	1		

POD, post-operative delirium; y, year; NSAIDs, non-steroidal anti-inflammatory drugs; ICU, intensive care unit. ^aMeans comparison between POD-J group and POD-E group using Chi-Squared test. The bold values refer to statistical significance (P < 0.05).



delirium subtypes. NSAIDs, non-steroidal anti-inflammatory drugs; COPD, chronic obstructive pulmonary disease.

lorazepam (20.97%) and midazolam (32.26%), followed by fentanyl analogs (43.55%), fentanyl (14.52%), remifentanil (8.06%), sufentanil (6.45%), flupentixol (30.65%), antibiotics (19.35%), and glucocorticoids (17.74%). The POD-Y group also exhibited a high incidence of mechanical ventilation (28.57%) and ICU admission (34.69%). The average length of hospitalization in the POD-Y group was 37.00 days, with a standard deviation of 55.44 days. A portion of the patients experienced recurrence (9.52%), and 1 patient (1.64%) died-including 1 female (1.64%) patient. The clinical characteristics and outcomes of post-operative delirium patients aged 65 years and older (POD-E) are presented in Table 1. We subsequently compared the data of patients aged 18 to 64 (POD-Y) with those of patients in the POD-E group and found that the clinical characteristics and prognoses of the patients in the two cohorts differed. There were significant differences in age between the two cohorts (45.81 \pm 13.52 vs. 77.16 \pm 7.62, P <0.001) and between females (45.93 \pm 12.61 vs. 76.71 \pm 7.97, P < 0.001) and males (45.70 \pm 14.30 vs. 77.54 \pm 7.27, P < 0.001) within each cohort. Moreover, common chronic diseases (25.00% vs. 60.98%, P < 0.001) were less common in the POD-Y group than in the POD-E group, especially hypertension (10.71% vs. 41.46%, P < 0.001). Among all the comorbidities, cardiovascular diseases (19.64% vs. 62.79%, P < 0.001) and urinary diseases

(5.36% vs. 23.26%, P = 0.009) were less prevalent in the POD-Y group than in the POD-E group. In addition, the rates of fentanyl analog (43.55% vs. 22.22%, P = 0.034) and lorazepam (20.97% vs. 5.56%, P = 0.041) use were greater in the POD-Y group than in the POD-E group; however, the rate of norepinephrine (0.00% vs. 13.89%, P = 0.011) use was lower. The incidence of adverse events, including anemia (0.00% vs. 14.63%, P = 0.012) and kidney failure (0.00% vs. 12.20%, P = 0.028), was lower in the POD-Y group than in the POD-E group. Furthermore, the overall inhospital mortality rate of POD-Y patients was lower than that of POD-E patients (1.64% vs. 20.45%, P = 0.004). Additionally, the mortality rates of male (0.00% vs. 25.00%, P < 0.001) and female (1.64% vs. 15.00%, P = 0.045) POD-Y patients were lower than those of POD-E patients. Additionally, using a heatmap, Figure 2A shows the data in Table 1, and a volcano plot was generated to show the differences and significance of the differences in clinical characteristics and outcomes between the POD-Y group and the POD-E group (Figure 3A).

The POD-J group consisted of 7 patients, with an average age of 6.94 ± 5.36 years, and 4 patients (57.15%) were male. The major reason for surgery in the POD-J group was neurological disorders (28.57%), and all patients underwent surgery under general anesthesia. During post-operative delirium, 5 patients in the POD-J



group were hyperactive (71.43%), and 2 patients had mixed symptoms (28.57%). Sevoflurane (83.33%), nitrous oxide (50.00%), lidocaine (50.00%), and propofol (33.33%) were frequently used for general anesthesia. The medicines that the POD-J group took most commonly were fentanyl analogs (71.43%), fentanyl (42.86%), followed by benzodiazepines (71.43%), midazolam (57.14%), and lorazepam (14.29%). In the POD-Y group, the incidence rates of adverse events, including abdominal pain (14.29%) and heart failure (14.29%), and the use of mechanical ventilation (14.29%), intensive care unit (14.29%), and recurrence rate (14.29%), were low. A total of 3 of the patients in the POD-J group died. Subsequently, we compared the clinical characteristics and outcomes between the POD-J and POD-E groups and found that the incidence of post-operative delirium following neurological surgeries was higher in the POD-J group than in the POD-E group (28.57% vs. 0.00%, P = 0.016). Additionally, sevoflurane (83.33% vs. 16.67%, P = 0.026) and nitrous oxide (50.00% vs. 0.00%, P =0.044) were more frequently used for anesthesia in the POD-J group than in the POD-E group. Furthermore, fentanyl analogs (71.43% vs. 22.22%, P = 0.032) were more commonly administered to the POD-J group than to the POD-E group. Notably, patients in the POD-J group have a higher mortality rate. Furthermore, there is no significant statistical difference in mortality rates between the POD-Y and POD-J groups. Figure 2A effectively illustrates the data from Table 2, while Figure 3B depicts a volcano plot that highlights the differences and significance in clinical characteristics and outcomes between the POD-J group and the POD-E group.

3.4 Clinical features and prognosis of patients with different subtypes of post-operative delirium

According to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), delirium is categorized into three subtypes: hyperactive delirium, hypoactive delirium and mixed delirium. The clinical manifestations of these subtypes range from a nearly unconscious state to a highly agitated state (17). In this study, we described the clinical characteristics and prognosis associated with each subtype, drawing insights from the analysis of case reports. The data are presented in Table 3.

Among 116 patients, 38 were diagnosed with hypoactive delirium, 63 with hyperactive delirium, and 15 with mixed delirium. The mean age and the proportion of males in the patient population for these groups were as follows: 60.58 ± 20.81 years and 52.63% male, 53.97 \pm 23.01 years and 55.56% male, and 52.67 \pm 21.75 years and 40.00% male, respectively. The predominant reasons for surgery in these cohorts were gastrointestinal diseases (Hypoactive group, 23.68%), cardiovascular diseases (Hyperactive group, 23.81%) and gastrointestinal diseases (Mixed group, 33.33%). General anesthesia was administered to the majority of patients in all three cohorts (92.31%, 94.64%, and 75.00%). A minority of patients in these groups had preexisting cognitive dysfunction (17.65%, 16.39%, and 0.00%) and a history of delirium (0.00%, 1.64%, and 7.41%). The patients in these three cohorts frequently had common chronic diseases (48.48%, 38.60%, and 20.00%), including hypertension (24.24%, 24.56%, and 13.33%), diabetes (21.21%, 21.05%, and 6.67%), dyslipidemia (15.15%, 5.26%, and 0.00%), coronary heart disease (6.06%, 8.77%, and 6.67%), asthma (9.09%, 3.51%, and 0.00%), and chronic obstructive pulmonary disease (3.03%, 7.02%, and 0.00%). The average durations of surgery in these three cohorts were 229.80 \pm 162.69, 206.40 \pm 128.34, and 148.00 \pm 76.79, respectively. Cardiovascular diseases were the most common comorbidities in both the hypoactive and hyperactive cohorts (42.42% and 35.59%, respectively), while the mixed cohort exhibited a greater incidence of cardiovascular diseases (26.67%) and gastrointestinal diseases (26.67%). Additionally, propofol (62.50% and 58.82%) was most frequently used for anesthesia in the hypoactive cohort and hyperactive cohort, and propofol (57.14%) and lidocaine (57.14%) were most commonly used for anesthesia in the mixed cohort. Patients in these cohorts commonly used non-steroidal anti-inflammatory drugs (25.81%, 15.52%, and 23.08%) and benzodiazepines (19.35%, 56.90%, and 76.92%) and experienced a notable incidence of arrhythmia (20.00%, 13.56%, and 26.67%). Post-surgery, mechanical ventilation (37.05%, 31.67%, and 28.57%) and intensive care unit admission (29.17%, 35.00%, and 28.57%) were prevalent across all three cohorts. The average hospitalization durations were 32.31 days (SD = 38.98 days), 26.73 days (SD = 44.88 days), and 40.00 days (SD = 48.09 days). Some patients experienced recurrence (12.12%, 15.00%, and 28.57%), with 4 patients (11.11%) in the hypoactive cohort, 4 patients (6.45%) in the hyperactive cohort, and 3 patients (20.00%) in the mixed cohort dying. Statistical analyses using the chi-square test revealed significant differences in the reasons for surgery, such as cardiovascular diseases (18.42% vs. 23.81% vs. 0.00%, P = 0.027), reproductive system diseases (5.26% vs. 1.59% vs. 20.00%, P = 0.043), and neurological disorders (0.00% vs. 7.94%) vs. 0.00%, P = 0.023). Patients with hyperactive delirium had a history of substance abuse (0.00% vs. 12.28% vs. 0.00%, P =0.020), a factor absent in the other cohorts. Notably, there were significant differences in the pharmacological treatments used among these cohorts of patients throughout their entire course of delirium. Compared with those in the other cohorts, patients in the hyperactive cohort used more fentanyl analogs (19.35% vs. 50.00% vs. 38.46%, P = 0.017) and flupentixol (12.90% vs. 39.66% vs. 30.77%, P = 0.025). Patients in the mixed cohort used more benzodiazepines (19.35% vs. 56.90% vs. 76.92%, P = 0.003) and diphenhydramine (3.23% vs. 3.45% vs. 23.08%, P = 0.038) than did patients in the other cohorts. To visualize the data, heatmaps (Figure 2B) and volcano plots (Figures 3C–E) were generated based on the data in Table 3 and Supplementary material 2.

4 Discussion

This study mainly investigated different age groups and delirium subtypes. Concerning age, previous research has focused primarily on the clinical manifestations and efficacy of pharmacological interventions following different surgical procedures in delirium patients aged older than 65 years (4, 9, 10) and in pediatric delirium patients (23-25). However, there is a lack of exploration into the clinical characteristics and prognosis of post-operative delirium in patients younger than 65 years. Previous research has suggested that post-operative delirium patients aged 18 to 65 typically exhibit lower incidence rates and experience more favorable outcomes compared to the elderly population, which is consistent with our findings (26). However, what has not been reported previously is that post-operative delirium patients younger than 18, as well as those aged 18 to 65 with mixed-subtype delirium, exhibited similar high mortality rates as elderly patients aged 65 and above (14.29% vs. 20.45%, P = 1). This implies that both concealed clinical presentations and poor prognoses may coexist in these two specific patient populations. Although this finding awaits confirmation from larger-scale clinical studies, it suggests the critical need for early recognition and intervention of these low-incidence, clinically subtle but high-risk patient groups in clinical practice. Our findings also indicate that patients under the age of 65 (POD-J and POD-Y) are more likely to use fentanyl analogs, and patients in the POD-Y cohort are more inclined to use lorazepam than are those aged 65 and above. This finding suggested a potential association between fentanyl analogs and delirium in patients in the POD-Y and POD-J cohorts. Additionally, one systematic review reported that opioid medications, including fentanyl, increase the risk of delirium (27), and another randomized controlled trial conducted on ventilated patients revealed that, when used for analgesia and sedation, fentanyl resulted in a greater incidence of delirium in hospitalized patients than did morphine (28). Conversely, the administration of benzodiazepines does not increase the incidence of post-operative delirium. However, this conclusion is based on lower-quality evidence (29). Therefore, determining whether benzodiazepines can increase the risk of delirium requires clinical randomized controlled trials with larger sample sizes, as well as systematic reviews and meta-analyses based on higher-quality evidence (30). General anesthesia is considered to potentially induce short-term neurological toxicity (such as post-operative delirium) and long-term cognitive impairment in children (31, 32). Among the patients under 18 years (POD-J),

TABLE 3 Clinical characteristics and outcomes of patients with different subtypes of post-operative delirium.

Clinical characteristics	Hypoactive	Hyperactive	Mixed	<i>p</i> -value ^a	
Number of patients	38	63	15		
Age (all)	60.58 ± 20.81	53.97 ± 23.01	52.67 ± 21.75	0.626	
Age (female)	63.06 ± 19.56	51.93 ± 21.40	52.78 ± 22.40	0.224	
Age (male)	58.35 ± 21.64	54.65 ± 24.18	52.50 ± 19.20	0.807	
Male	20/38 (52.63%)	35/63 (55.56%)	6/15 (40.00%)	0.555	
Reasons for surgery					
Skeletal disorders	5/38 (13.16%)	14/63 (22.22%)	3/15 (20.00%)	0.444	
Cardiovascular diseases	7/38 (18.42%)	15/63 (23.81%)	0/15 (0.00%)	0.027	
Gastrointestinal diseases	9/38 (23.68%)	8/63 (12.70%)	5/15 (33.33%)	0.133	
Malignant neoplasm	4/38 (10.53%)	8/63 (12.70%)	0/15 (0.00%)	0.163	
Respiratory diseases	5/38 (13.16%)	2/63 (3.17%)	0/15 (0.00%)	0.120	
Ophthalmic diseases	3/38(7.89%)	0/63 (0.00%)	0/15 (0.00%)	0.077	
Reproductive system diseases	2/38 (5.26%)	1/63 (1.59%)	3/15 (20.00%)	0.043	
Neurological disorders	0/38 (0.00%)	5/63 (7.94%)	0/15 (0.00%)	0.023	
Urological disorders	0/38 (0.00%)	2/63 (3.17%)	1/15 (6.67%)	0.234	
Others	3/38 (7.89%)	8/63 (12.70%)	3/15 (20.00%)	0.476	
Anesthesia					
Regional	2/26 (7.69%)	3/56 (5.36%)	3/12 (25.00%)	0.222	
General	24/26 (92.31%)	53/56 (94.64%)	9/12 (75.00%)	0.222	
Preexisting cognitive dysfunction	6/34 (17.65%)	10/61 (16.39%)	0/14 (0.00%)	0.163	
Delirium history	0/33 (0.00%)	1/61 (1.64%)	1/14 (7.41%)	0.335	
Disease history					
Smoke	1/33 (3.03%)	6/57 (10.53%)	2/15 (13.33%)	0.515	
Alcohol	2/33 (6.06%)	6/57 (21.05%)	1/15 (6.67%)	0.811	
Drugs (cocaine etc.)	0/33 (0.00%)	7/57 (12.28%)	0/15 (0.00%)	0.020	
Common chronic disease	16/33 (48.48%)	22/57 (38.60%)	3/15 (20.00%)	0.164	
Dyslipidemia	5/33 (15.15%)	3/57 (5.26%)	0/15 (0.00%)	0.131	
Diabetes	7/33 (21.21%)	6/57 (21.05%)	1/15 (6.67%)	0.307	
Hypertension	8/33 (24.24%)	14/57 (24.56%)	2/15 (13.33%)	0.657	
Coronary heart disease	2/33 (6.06%)	5/57 (8.77%)	1/15 (6.67%)	0.884	
Asthma	3/33 (9.09%)	2/57 (3.51%)	0/15 (0.00%)	0.424	
COPD	1/33 (3.03%)	4/57 (7.02%)	0/15 (0.00%)	0.690	
Time of surgery					
Mean \pm SD min	229.80 ± 162.69	206.40 ± 128.34	148.00 ± 76.79	0.601	
Comorbidities					
Cardiovascular	14/33 (42.42%)	21/59 (35.59%)	4/15 (26.67%)	0.567	
Gastrointestinal	6/33 (18.18%)	8/59 (13.56%)	4/15 (26.67%)	0.557	
Central nervous system	6/33 (18.18%)	9/59 (28.81%)	3/15 (20.00%)	0.879	
Respiratory	7/33 (21.21%)	8/59 (13.56%)	0/15 (0.00%)	0.081	
Hematological	1/33 (3.03%)	2/59 (3.39%)	2/15 (13.33%)	0.266	
Urinary	4/33 (12.12%)	8/59 (13.56%)	1/15 (6.67%)	0.787	

TABLE 3 (Continued)

Clinical characteristics	Hypoactive	Hyperactive	Mixed	<i>p</i> -value ^a	
Mental disorders	7/33 (21.21%)	12/59 (20.34%)	3/15 (20.00%)	1	
Anxiety	1/33 (3.03%)	4/59 (6.78%)	1/15 (6.67%)	0.725	
Depression	3/33 (9.09%)	3/59 (5.08%)	1/15 (6.67%)	0.862	
Cancer	3/33 (9.09%)	11/59 (18.64%)	2/15 (13.33%)	0.800	
Else	16/33 (48.48%)	9/59 (28.81%)	2/15 (13.33%)	0.002	
Anesthetic drugs					
Sevoflurane	3/8 (37.50%)	14/34 (41.18%)	1/7 (14.29%)	0.438	
Isoflurane	3/8 (37.50%)	3/34 (8.82%)	1/7 (14.29%)	0.188	
Nitrous oxide	2/8 (25.00%)	4/34 (11.76%)	2/7 (28.57%)	0.608	
Propofol	5/8 (62.50%)	20/34 (58.82%)	4/7 (57.14%)	1	
Ketamine	2/8 (25.00%)	2/34 (5.88%)	1/7 (14.29%)	0.160	
Thiopental sodium	1/8 (12.50%)	2/34 (5.88%)	0/7 (0.00%)	0.572	
Lidocaine	2/8 (25.00%)	10/34 (29.41%)	4/7 (57.14%)	0.428	
Bupivacaine	1/8 (12.50%)	1/34 (2.94%)	1/7 (14.29%)	0.218	
Medicine					
Fentanyl analogs	6/31 (19.35%)	29/58 (50.00%)	5/13 (38.46%)	0.017	
Fentanyl	1/31 (3.23%)	16/58 (27.59%)	1/13 (7.70%)	0.006	
Sufentanil	1/31 (3.23%)	2/58 (3.45%)	2/13 (15.39%)	0.190	
Remifentanil	0/31 (0.00%)	3/58 (5.17%)	2/13 (15.39%)	0.101	
Morphine	5/31 (16.13%)	11/58 (18.97%)	5/13 (38.46%)	0.267	
Hydrocodone	3/31 (9.68%)	5/58 (8.62%)	0/13 (0.00%)	0.459	
Succinylcholine	3/31 (9.68%)	3/58 (5.17%)	1/13 (7.70%)	0.542	
Vecuronium	3/31 (9.68%)	2/58 (3.45%)	0/13 (0.00%)	0.401	
Rocuronium	4/31 (12.90%)	5/58 (8.62%)	0/13 (0.00%)	0.300	
Benzodiazepines	6/31 (19.35%)	33/58 (56.90%)	10/13 (76.92%)	0.003	
Lorazepam	0/31 (0.00%)	12/58 (20.69%)	4/13 (30.77%)	0.002	
Midazolam	6/31 (19.35%)	18/58 (31.03%)	6/13 (46.15%)	0.213	
Dexmedetomidine	1/31 (3.23%)	7/58 (12.07%)	2/13 (15.38%)	0.424	
Diphenhydramine	1/31 (3.23%)	2/58 (3.45%)	3/13 (23.08%)	0.038	
Chlorpromazine	0/31 (0.00%)	5/58 (8.62%)	0/13 (0.00%)	0.245	
Flupentixol	4/31 (12.90%)	23/58 (39.66%)	4/13 (30.77%)	0.025	
Quetiapine	1/31 (3.23%)	8/58 (13.79%)	1/13 (7.70%)	0.327	
Olanzapine	0/31 (0.00%)	6/58 (10.34%)	1/13 (7.70%)	0.140	
NSAIDs	8/31 (25.81%)	9/58 (15.52%)	3/13 (23.08%)	0.533	
Aspirin	4/31 (12.90%)	2/58 (3.45%)	1/13 (7.70%)	0.208	
Atropine	3/31 (9.68%)	3/58 (5.17%)	4/13 (30.77%)	0.068	
Neostigmine	5/31 (16.13%)	3/58 (5.17%)	1/13 (7.70%)	0.355	
Glucocorticoids	5/31 (16.13%)	7/58 (12.07%)	3/13 (23.08%)	0.572	
Furosemide	3/31 (9.68%)	2/58 (3.45%)	2/13 (15.38%)	0.172	
Catecholamines	6/31 (19.35%)	4/58 (6.90%)	4/13 (30.77%)	0.055	
Epinephrine	2/31 (6.45%)	2/58 (3.45%)	3/13 (23.08%)	0.046	

TABLE 3 (Continued)

Clinical characteristics	Hypoactive	Hyperactive	Mixed	<i>p</i> -value ^a
Norepinephrine	3/31 (9.68%)	2/58 (3.45%)	0/13 (0.00%)	0.401
Dopamine	1/31 (3.23%)	2/58 (3.45%)	1/13 (7.70%)	0.594
Statins	1/31 (3.23%)	3/58 (5.17%)	1/13 (7.70%)	0.670
Ondansetron	0/31 (0.00%)	7/58 (12.07%)	2/13 (15.38%)	0.043
Antibiotics	5/31 (16.13%)	13/58 (22.41%)	5/13 (38.46%)	0.313
Adverse events				
Post-operative hypotension	2/30 (6.67%)	3/59 (5.08%)	1/15 (6.67%)	1
Post-operative hypertension	2/30 (6.67%)	3/59 (5.08%)	1/15 (6.67%)	1
Arrhythmia	6/30 (20.00%)	8/59 (13.56%)	4/15 (26.67%)	0.521
Anemia	2/30 (6.67%)	2/59 (3.39%)	2/15 (13.33%)	0.273
Kidney failure	2/30 (6.67%)	1/59 (1.69%)	2/15 (13.33%)	0.078
Else	21/30 (70.00%)	19/59 (32.20%)	9/15 (60.00%)	0.002
ICU	7/24 (29.17%)	21/60 (35.00%)	4/14 (28.57%)	0.823
Mechanical ventilation	9/24 (37.50%)	19/60 (31.67%)	4/14 (28.57%)	0.863
Days of hospitalization				
Mean \pm SD day	32.31 ± 38.98	26.73 ± 44.88	40.00 ± 48.09	0.851
Recurrence	4/33 (12.12%)	9/60 (15.00%)	4/14 (28.57%)	0.430
Follow-up	11/38 (28.95%)	14/63 (22.22%)	3/15 (20.00%)	0.747
Outcome				
Death (all)	4/36 (11.11%)	4/62 (6.45%)	3/15 (20.00%)	0.390
Death (female)	1/16 (6.25%)	2/27 (7.41%)	1/9 (11.11%)	1
Death (male)	3/20 (15.00%)	2/35 (5.71%)	2/6 (33.33%)	0.128

POD, post-operative delirium; y, year; COPD, chronic obstructive pulmonary disease; SD, Standard Deviation; min, minutes; NSAIDs, non-steroidal anti-inflammatory drugs; ICU, intensive care unit. ^aMeans comparison between hypoactive group, hyperactive group and mixed group using Chi-Squared test. The bold values refer to statistical significance (*P* < 0.05).

sevoflurane and nitrous oxide were more commonly used for general anesthesia than were used in the POD-E group. Sevoflurane and desflurane can lead to early awakening after anesthesia, potentially contributing to the development of delirium (33), and the use of nitrous oxide may result in subacute toxic delirium (34). However, in the elderly patient population, there was no increase in the incidence of post-operative delirium in patients exposed to nitrous oxide compared to those not exposed to nitrous oxide (35). Therefore, the use of sevoflurane may be associated with the occurrence of post-operative delirium in children, but the relationship between nitrous oxide and post-operative delirium is still unclear. Previous research has emphasized the strong association between different subtypes and distinct clinical presentations and prognoses. Specifically, hyperactive delirium has shown significant correlations with factors such as age, procalcitonin levels, frailty, and overall health status (36). A survey revealed that the hypoactive subtype was the most common subtype in ICU (20). Additionally, hyperactive delirium is easier to recognize and treat, while hypoactive delirium, characterized by lethargy and confusion, is often misdiagnosed. Hypoactive delirium, due to delayed diagnosis, has the highest mortality rate and consumes more healthcare resources (36, 37). In addition, studies have also revealed the incidence and prevalence of different delirium subtypes. To further understand the pathophysiological mechanisms of post-operative delirium in these three subtypes, more clinical data and specific analyses related to these subtypes are required (4, 38-40). Our study addresses this gap by conducting a retrospective analysis of the clinical characteristics and prognosis of hyperactive, hypoactive, and mixed delirium patients. Our data revealed a significant association between hyperactive disease and a history of substance abuse. Additionally, our findings align with a study on acute delirium and non-compliance in patients with a history of substance abuse after total hip replacement surgery, suggesting that a cumulative effect of excessive alcohol use and drug abuse increases the risk of post-operative delirium and psychiatric disorders (41). This suggests that patients with a history of substance abuse may, during their hospital stay, eventually manifest hyperactive delirium as a result of the combined effects of withdrawal reactions and delirium (42). Thus, in patients with a history of substance abuse and multiple post-operative delirium risk factors (43), heightened vigilance is crucial to anticipate hyperactive delirium and implement timely intervention measures. Our study also highlights associations, such as the high usage of fentanyl and flupentixol with hyperactive delirium and the high usage of diphenhydramine, benzodiazepines, epinephrine, and

ondansetron with mixed delirium. Different delirium subtypes involve distinct pathophysiological mechanisms, and various drugs potentially contribute to these mechanisms, resulting in imbalances in neurotransmitters such as acetylcholine, gamma-aminobutyric acid, and dopamine, ultimately leading to the manifestation of different subtypes in patients (44).

5 Limitations

Previous studies have often focused on elderly post-operative delirium patients aged over 65, with relatively less attention paid to those under 65. This younger population tends to present with a more insidious onset and a lower incidence of delirium, and is often overlooked by clinical practitioners. Therefore, we chose to collect case reports from online databases as the data source for our systematic review. However, case reports are generally considered to be of lower evidence quality and cannot provide the same level of inference as higher-tier studies such as randomized controlled trials (RCTs) or cohort studies. Additionally, there is significant heterogeneity among case reports, with variations in study design, data collection methods, diagnostic criteria, and interventions. This heterogeneity complicates data synthesis and may affect the overall consistency of the systematic review. Online case reports also tend to highlight rare or unique cases, while more common or negative outcomes may be underreported, leading to publication bias. Moreover, not all case reports adhere to standardized reporting guidelines, and some may lack critical data or details, which can affect the comprehensiveness and accuracy of the systematic review. In addition, it is challenging to control for potential confounding variables in the study, such as specific surgical techniques, the complex effects of multiple comorbidities, and perioperative management protocols, all of which may influence the measurement of delirium incidence and outcomes.

6 Conclusions

Our investigation has revealed noteworthy insights into post-operative delirium in different patient populations. Notably, age emerged as a pivotal factor. Compared to the POD-E group, the POD-Y group demonstrate fewer chronic medical conditions, fewer comorbidities, a lower incidence of adverse events, and lower mortality rates. Additionally, the POD-J group have higher rates of fentanyl analog use and a higher incidence of delirium following neurosurgical procedures compared to the POD-E group. Additionally, a strong association was found between a history of substance abuse and hyperactive delirium. Variations in drug use patterns were observed across different subtypes, indicating potential differences in symptomatology and clinical presentations. Importantly, postoperative delirium patients younger than 18 years (POD-J group), as well as those aged 18 to 65 with mixed-subtype delirium, exhibited similar high mortality rates as elderly patients. This underscores the need for increased attention to post-operative delirium patients under 65 and highlights the necessity of rapid identification and early intervention for these populations at risk of poor outcomes.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

JG: Conceptualization, Formal analysis, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing. XG: Conceptualization, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing. WL: Data curation, Methodology, Resources, Software, Writing – review & editing. AZ: Data curation, Methodology, Resources, Software, Writing – review & editing. JH: Data curation, Methodology, Resources, Software, Writing – review & editing. LD: Data curation, Methodology, Resources, Software, Writing – review & editing. YZ: Data curation, Methodology, Resources, Software, Writing – review & editing. LD: Data curation, Methodology, Resources, Software, Writing – review & editing. YZ: Data curation, Methodology, Resources, Software, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by Medical Scientific Research Foundation of Guangdong Province, China (A2023471) and the Zhongshan Social Public Welfare and Basic Research Program (2021B1055).

Conflict of interest

The authors declare the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024. 1465681/full#supplementary-material

References

1. Rieck KM, Pagali S, Miller DM. Delirium in hospitalized older adults. *Hosp Pract.* (2020) 48:3–16. doi: 10.1080/21548331.2019.1709359

2. Dechnik A, Traube C. Delirium in hospitalised children. Lancet Child Adolesc Health. (2020) 4:312–21. doi: 10.1016/S2352-4642(19)30377-3

3. Jin Z, Hu J, Ma D. Post-operative delirium: perioperative assessment, risk reduction, and management. *Br J Anaesth.* (2020) 125:492–504. doi: 10.1016/j.bja.2020.06.063

4. Li T, Li J, Yuan L, Wu J, Jiang C, Daniels J, et al. Effect of regional vs general anesthesia on incidence of post-operative delirium in older patients undergoing hip fracture surgery: the RAGA randomized trial. *JAMA*. (2022) 327:50–8. doi: 10.1001/jama.2022.3544

5. Wang YY, Yue JR, Xie DM, Carter P, Li QL, Gartaganis SL, et al. Effect of the Tailored, family-involved hospital elder life program on post-operative delirium and function in older adults: a randomized clinical trial. *JAMA Intern Med.* (2020) 180:17–25. doi: 10.1001/jamainternmed.2019.4446

6. Richi N, Toshiya F, Yosuke K, Tetsuya O, Morihiko I, Yoshiteru T, et al. C reactive protein albumin ratio as a new predictor of post-operative delirium after cholecystectomy for acute cholecystitis. *Sci Rep.* (2024) 14:21704. doi: 10.1038/s41598-024-72856-4

7. Ruan X, Li Y, Yuan M, Li H, Lou J, Liu Y, et al. Preoperative serum ferritin as a biomarker for predicting delirium among elderly patients receiving non-cardiac surgery: a retrospective cohort study. *Transl Psychiatry.* (2024) 14:377. doi: 10.1038/s41398-024-03090-9

8. Evered LA, Chan MTV, Han R, Chu MHM, Cheng BP, Scott DA, et al. Anaesthetic depth and delirium after major surgery: a randomised clinical trial. *Br J Anaesth.* (2021) 127:704–12. doi: 10.1016/j.bja.2021.07.021

9. Shin HJ, Woo Nam S, Kim H, Yim S, Han SH, Hwang JW, et al. Post-operative delirium after dexmedetomidine versus propofol sedation in healthy older adults undergoing orthopedic lower limb surgery with spinal anesthesia: a randomized controlled trial. *Anesthesiology.* (2023) 138:164–71. doi: 10.1097/ALN.000000000004438

10. Wildes TS, Mickle AM, Ben Abdallah A, Maybrier HR, Oberhaus J, Budelier TP, et al. Effect of electroencephalography-guided anesthetic administration on postoperative delirium among older adults undergoing major surgery: the ENGAGES randomized clinical trial. *JAMA*. (2019) 321:473–83. doi: 10.1001/jama.2018.22005

11. Xiang PY, Boyle L, Short TG, Deng C, Campbell D. Incidence of post-operative delirium in surgical patients: an observational retrospective cohort study. *Anaesth Intensive Care.* (2023) 51:260–7. doi: 10.1177/0310057X231156459

12. Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensusbased guideline on post-operative delirium. *Eur J Anaesthesiol.* (2017) 34:192–214. doi: 10.1097/EJA.00000000000594

13. Leslie DL, Inouye SK. The importance of delirium: economic and societal costs. *J Am Geriatr Soc.* (2011) 59(Suppl 2):S241-3. doi: 10.1111/j.1532-5415.2011.03671.x

14. Pezzullo L, Streatfeild J, Hickson J, Teodorczuk A, Agar MR, Caplan GA. Economic impact of delirium in Australia: a cost of illness study. *BMJ Open.* (2019) 9:e027514. doi: 10.1136/bmjopen-2018-027514

15. Cavallari M, Dai W, Guttmann CRG, Meier DS, Ngo LH, Hshieh TT, et al. Neural substrates of vulnerability to postsurgical delirium as revealed by presurgical diffusion MRI. *Brain.* (2016) 139:1282–94. doi: 10.1093/brain/aww010

16. Rubia K. Functional brain imaging across development. Eur Child Adolesc Psychiatry. (2012) 22:719–31. doi: 10.1007/s00787-012-0291-8

17. Zhou W, Bai X, Yang Y, Huang M, Zheng Q, Wu J, et al. Revelations of delirium subtype research: a bibliometric analysis of publications in the past twenty years in the field. *Asian J Psychiatr.* (2023) 83:103561. doi: 10.1016/j.ajp.2023.103561

18. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet.* (2014) 383:911–22. doi: 10.1016/S0140-6736(13)60688-1

19. Krewulak KD, Stelfox HT, Leigh JP, Ely EW, Fiest KM. Incidence and prevalence of delirium subtypes in an adult ICU: a systematic review and meta-analysis. *Crit Care Med.* (2018) 46:2029–35. doi: 10.1097/CCM.00000000003402

20. Bowman EML, Cunningham EL, Page VJ, McAuley DF. Phenotypes and subphenotypes of delirium: a review of current categorisations and suggestions for progression. *Crit Care.* (2021) 25:334. doi: 10.1186/s13054-021-03752-w

21. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI Manual for Evidence Synthesis. JBI (2020). doi: 10.46658/JBIMES-24-01

22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Int J Surg.* (2021) 88:105906. doi: 10.1016/j.ijsu.2021.105906

23. Shi M, Miao S, Gu T, Wang D, Zhang H, Liu J. Dexmedetomidine for the prevention of emergence delirium and post-operative behavioral changes in pediatric

patients with sevoflurane anesthesia: a double-blind, randomized trial. *Drug Des Devel Ther.* (2019) 13:897–905. doi: 10.2147/DDDT.S196075

24. Staveski SL, Pickler RH, Khoury PR, Ollberding NJ, Donnellan AL, Mauney JA, et al. Prevalence of ICU delirium in post-operative pediatric cardiac surgery patients. *Pediatr Crit Care Med.* (2021) 22:68–78. doi: 10.1097/PCC.00000000002591

25. Urits I, Peck J, Giacomazzi S, Patel R, Wolf J, Mathew D, et al. Emergence delirium in perioperative pediatric care: a review of current evidence and new directions. Adv Ther. (2020) 37:1897–909. doi: 10.1007/s12325-020-01317-x

26. Serpytis P, Navickas P, Navickas A, Serpytis R, Navickas G, Glaveckaite S. Ageand gender-related peculiarities of patients with delirium in the cardiac intensive care unit. *Kardiol Pol.* (2017) 75:1041–50. doi: 10.5603/KP.a2017.0122

27. Swart LM, van der Zanden V, Spies PE, de Rooij SE, van Munster BC. The comparative risk of delirium with different opioids: a systematic review. *Drugs Aging*. (2017) 34:437–43. doi: 10.1007/s40266-017-0455-9

28. Casamento A, Neto AS, Lawrence M, Chudleigh L, Browne E, Taplin C, et al. Delirium in ventilated patients receiving fentanyl and morphine for Analgosedation: findings from the ANALGESIC trial. *J Crit Care.* (2023) 77:154343. doi: 10.1016/j.jcrc.2023.154343

29. Wang E, Belley-Cote EP, Young J, He H, Saud H, D'Aragon F, et al. Effect of perioperative benzodiazepine use on intraoperative awareness and post-operative delirium: a systematic review and meta-analysis of randomised controlled trials and observational studies. *Br J Anaesth.* (2023) 131:302–13. doi: 10.1016/j.bja.2022.12.001

30. Evered LA, Pryor KO. Benzodiazepines and post-operative delirium: should we be as cautious as we are? *Br J Anaesth*. (2023) 131:629–31. doi: 10.1016/j.bja.2023.07.004

31. McCann ME, Soriano SG. Does general anesthesia affect neurodevelopment in infants and children? *BMJ.* (2019) 367:l6459. doi: 10.1136/bmj.l6459

32. Schneuer FJ, Bentley JP, Davidson AJ, Holland AJ, Badawi N, Martin AJ, et al. The impact of general anesthesia on child development and school performance: a population-based study. *Paediatr Anaesth.* (2018) 28:528–36. doi: 10.1111/pan.13390

33. Moore AD, Anghelescu DL. Emergence delirium in pediatric anesthesia. *Paediatr Drugs*. (2017) 19:11–20. doi: 10.1007/s40272-016-0201-5

34. Gillman MA, Lichtigfeld FJ, Sandyk R. Subacute toxic delirium caused by nitrous oxide may be an acute withdrawal state. *Arch Neurol.* (1984) 41:704. doi: 10.1001/archneur.1984.04050180026006

35. Leung JM, Sands LP, Vaurio LE, Wang Y. Nitrous oxide does not change the incidence of post-operative delirium or cognitive decline in elderly surgical patients. *Br J Anaesth.* (2006) 96:754–60. doi: 10.1093/bja/ael106

36. Zhang X, Zhu W, Wang C, Zhou X, Chen Q, Jiang Y. Exploration of the factors affecting different delirium subtypes in hospitalized COVID-19 patients: a multicentre cross-sectional study. *Sci Rep.* (2024) 14:19454. doi: 10.1038/s41598-024-69925-z

37. Evensen S, Bourke AK, Lydersen S, Sletvold O, Saltvedt I, Wyller TB, et al. Motor activity across delirium motor subtypes in geriatric patients assessed using body-worn sensors: a Norwegian cross-sectional study. *BMJ Open.* (2019) 9:e026401. doi: 10.1136/bmjopen-2018-026401

38. Jiang JL, Zhang L, He LL, Yu H, Li XF Dai SH, et al. Volatile versus total intravenous anesthesia on post-operative delirium in adult patients undergoing cardiac valve surgery: a randomized clinical trial. *Anesth Analg.* (2023) 136:60–9. doi: 10.1213/ANE.00000000006257

39. Perez-Otal B, Aragon-Benedi C, Pascual-Bellosta A, Ortega-Lucea S, Martinez-Ubieto J, Ramirez-Rodriguez JM, et al. Neuromonitoring depth of anesthesia and its association with post-operative delirium. *Sci Rep.* (2022) 12:12703. doi: 10.1038/s41598-022-16466-ys

40. Yang JJ, Lei L, Qiu D, Chen S, Xing LK, Zhao JW, et al. Effect of remimazolam on post-operative delirium in older adult patients undergoing orthopedic surgery: a prospective randomized controlled clinical trial. *Drug Des Devel Ther.* (2023) 17:143–53. doi: 10.2147/DDDT.S392569

41. Yu YH, Chen AC, Hu CC, Hsieh PH, Ueng SW, Lee MS. Acute delirium and poor compliance in total hip arthroplasty patients with substance abuse disorders. *J Arthroplasty.* (2012) 27:1526–9. doi: 10.1016/j.arth.2011.12.003

42. Gaetano R, De Filippis R, Caroleo M, Segura-Garcia C, De Fazio P. Postoperative heroin-withdrawal delirium treated with clonazepam after urgent cardiac surgery: a case report. *Riv Psichiatr.* (2020) 55:366–70. doi: 10.1708/3503.34895

43. van Velthuijsen EL, Zwakhalen SMG, Mulder WJ, Verhey FRJ, Kempen G. Detection and management of hyperactive and hypoactive delirium in older patients during hospitalization: a retrospective cohort study evaluating daily practice. *Int J Geriatr Psychiatry.* (2018) 33:1521–9. doi: 10.1002/gps.4690

44. Stagno D, Gibson C, Breitbart W. The delirium subtypes: a review of prevalence, phenomenology, pathophysiology, and treatment response. *Palliat Support Care.* (2004) 2:171–9. doi: 10.1017/S1478951504040234